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Abstract
Improved understanding of the molecular mechanisms has led to identification of check-
point signalling and development of checkpoint inhibitors in the treatment of many 
cancers, including lung cancer. To be able to select the patients who benefit most from 
checkpoint inhibitors, predictive biomarkers are needed. Currently, the only predictive 
biomarker that has been approved in clinical use is PD-L1, the ligand of the inhibitory 
T-cell checkpoint PD-1. The use of PD-L1 as a predictive biomarker is confounded by 
multiple unresolved issues, from testing issues (e.g., cut-off values for positivity) to clini-
cal use (e.g., the response to anti–PD-1 and anti–PD-L1 antibodies in patients without 
any expression of PD-L1). Even more open questions exist in the evaluation of PD-L1 
as a prognostic biomarker. In the future, we expect that an improved understanding of 
immune system, tumor microenvironment, mechanism of action of immunotherapeutic 
drugs, and PD-L1 testing methods will elucidate the value of PD-L1 as a prognostic and 
predictive biomarker in detail.
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1. Introduction
Immunotherapy represents an important step forward in the management of patients with 
lung cancer. Careful selection of patients, who benefit most from any new treatment includ-
ing immunotherapy, is essential. To be able to select the patients, prognostic and predictive 
markers are needed. Prognostic biomarkers provide information about the patient’s overall 
cancer outcome, regardless of the therapy. Predictive biomarkers give information about the 
effect of a therapeutic intervention [1–3].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
PD-1 is a T cell immune checkpoint involved in dampening autoimmunity in the peripheral 
effector phase of T-cell activation, leading to immune tolerance of cells expressing its ligands 
PD-L1 and PD-L2. Activation of PD-1–PD-L1 leads to peripheral immunological tolerance in 
T cells. Multiple solid tumors (melanoma, RCC, and lung cancer) express PD-L1 to gener-
ate immunosuppressive tumor microenvironment and avoid destruction of their cells by T 
lymphocytes. In healthy tissues, PD-1 is thought to limit the activity of antigen-specific T 
cells to prevent collateral tissue damage during infection. In cancer, the PD-1 pathway can be 
exploited by some tumor cells to inactivate T cells [4].
The importance of the PD-L1 together with the development of drugs that inhibit its action 
suggest a candidate for a prognostic and/or predictive biomarker: PD-L1 expression in 
tumor or inflammatory cells. The (few) trials that evaluated PD-L1 as a prognostic biomarker 
yielded inconclusive results. Some of them showed that patients with PD-L1 or PD-1 positive 
expression have significantly shorter overall survival, while in others, no correlation between 
biomarker expression and outcome was seen. Many questions remain open even when consid-
ering PD-L1 as a predictive biomarker, for example, what cut-off percentage of expression can 
be considered as positive or can PD-L1 testing be performed only on fresh or archival tissues 
also. Above all, the most important question whether PD-L1 can really be considered as a pre-
dictive biomarker still has to be answered. In the lack of definitive answers, currently research-
ers propose other biomarkers as supplemental (e.g., pre-existing CD8+ T, cytokines, …) [4].
In this chapter, the value of PD-L1 as a prognostic and predictive biomarker will be presented 
together with all open questions and possible answers.
2. Change in the insight of lung cancer
Lung cancer was first described a century ago, and since then every year, around 1.6 million 
of new cases are diagnosed [4]. Nonsmall cell lung cancer (NSCLC) remains the main cause 
of death due to cancer worldwide. About 60% of lung cancers are diagnosed at Stage IV, and 
these patients have a very poor prognosis, since 5-year survival is only 1–4% [5]. New treat-
ments, developed in the last years, lead to improved survival in the different groups of NSCLC 
patients with advanced disease. Patients who benefit most are those with adenocarcinomas 
and specific mutations, such as EGFR activating mutations and ALK translocations. A median 
survival of 20 months has been reached with EGFR tyrosine kinase inhibitors (EGFR-TKI), 
which can be considered a milestone in the treatment of advanced lung cancer. Despite prom-
ising results, many patients with advanced lung cancer still have a poor prognosis. Patients 
with squamous carcinomas, patients with adenocarcinomas not harboring specific mutations, 
and patients with small cell lung cancers still have a poor prognosis, with survival often less 
than a year. To be able to improve survival in lung cancer in general, the next step should be 
to focus on the treatment of those patients. Immunotherapy nowadays seems a step forward 
in reaching this goal [1].
Changes in lung cancer have became evident in recent years. A strong connection between 
lung cancer and smoking is supposed to be one of the main reasons [4]. Main changes observed 
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are the increase of adenocarcinomas at the expense of squamous tumors and a change in 
the position of cancers. Previously centrally located, they now arise mainly at the periphery 
of the lung. Possible explanations are changes in the smoking patterns. Nicotine is known 
to be one of the most addictive substances in the world. To be able to get enough nicotine 
with new sorts of cigarettes (light and ultra light low-nicotine, and low-tar), smokers have to 
inhale deeper and for a longer time. This leads to the change of locations of tumors, since the 
smoke now enters deeply in the lungs and stays there for a longer time [6–8]. The increased 
incidence of adenocarcinomas is also suspected to be related to new forms of cigarettes and a 
higher amount of nitrosamines in them. Nitrosamines are known to cause adenocarcinomas 
in experimental animal models, and it is supposed that the same carcinogenic process occurs 
also in smokers [4, 9].
In recent years, changes at the “macroscopic level” are supplemented by the insight in the 
microscopic world of the lung cancer such as discovery of EGFR mutations and more and 
more important knowledge about complex immunologic interactions between tumors and 
the host environment [1].
3. Immune system and cancer
When cells transform to be malignant, activation of innate and adaptive immune responses 
occurs. The purpose of this activation is control of early cancer growth by elimination of can-
cer cells. Cancer cells have different genetic and epigenetic alterations leading to an expres-
sion of different antigens that can be recognized and eliminated by the immune system [10].
The process starts at the cancer site, where tumor cells disintegrate and tumor antigens become 
available to the immune system. Antigen presenting cells (APC) uptake these antigens and 
under maturation, signals, activate, and migrate to the lymph nodes or tertiary lymphoid 
structures [11]. Maturation signals are necessary, since without them immune tolerance rather 
than activation occurs. Examples of maturation signals are intracellular proteins, heat-shock 
proteins, DNA, ATP, uric acid, etc. Activated APCs migrate to lymph nodes, where they pres-
ent as antigens in the context of mayor histocompatibility complex Classes I and II molecules to 
the T lymphocytes. Antigen-specific CD 4 and CD 8 T lymphocytes recognize the antigens and 
become activated. Costimulatory and coinhibitory signals are essential for this activation to 
regulate and balance a proper immunological response. CD 28 complex represents a costimu-
latory signal and acts together with other stimulatory and inhibitory signals on T lymphocytes. 
They regulate T-cell activation, differentiation, survival, and effector function. Examples of 
costimulatory receptors are GITR, OX 40, CD 30, and CD 40, while coinhibitory signals, beside 
LAG, TIM, BTLA, VISTA, etc., include also CTLA-4 and PD-1 with its ligand PD-L1 currently 
implemented as important targets of cancer immunotherapy. After activation, T lymphocytes 
migrate to the tumors trough and the systemic vasculature by following a chemokine gradi-
ent. T cells then go through the process of extravasation, migrate into the tumor, and recognize 
the tumor targets that lead finally to tumor cell destruction [11]. Lymphocytic infiltration of 
tumors is frequently observed in a variety of human cancers and in numerous trials tumor-
infiltrating lymphocytes have been correlated with a more favorable prognosis [10].
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When tumors develop, tumor cells acquire several mutations that lead to tumor “immortality.” 
The results of these mutations are abnormal proteins on the cell surface that can be recognized 
by the immune system. A higher number of mutations, commonly called mutation burden, is 
connected to higher immunogenicity of tumors. NSCLC and melanomas are cancers with the 
highest burden among several solid tumors and because of that they are believed to be good 
targets for immunotherapy [1]. The problem of immune recognition and cancer is that cancers 
have the ability to evade the immune system, and this is one of the hallmarks of cancer [5]. 
Several mechanisms of immune evasion exist, but one of the most important is that tumor-
infiltrating lymphocytes become inactivated by the effect of PD-L1 expression on tumor cells 
[10, 12].
4. Why do we need prognostic and predictive biomarkers
Prognostic and predictive biomarkers have become important in recent years with the devel-
opment of new highly selective therapies. A prognostic biomarker offers insight into the pos-
sible natural evolvement of the disease and most likely outcome like duration of survival of 
the patients. It is not related to treatment, but rather to tumor biology. It helps physicians and 
patients to predict the course of the disease [1, 13–15]. Before a marker is labelled predictive, 
the effect of a marker as a prognostic marker must be taken into account [16].
A predictive biomarker, on the other hand, predicts the effect of the treatment that should be 
different in patients with the biomarker compared to those without it [1, 7]. In lung cancer, 
examples of predictive biomarkers include the presence of EGFR-activating mutations and 
response to EGFR-TKIs. Predictive biomarkers are important in treatment decisions because 
they can improve the treatment effectiveness and at the same time, reduce costs and poten-
tial harm to the patients by avoiding treatment when the biomarker is not present [1]. In a 
trial presented by Lopes et al., the use of biomarkers to select proper patients in clinical trials 
resulted in a sixfold increase in clinical trial success [17].
Regarding immunotherapy, the median duration of response, once the response is achieved, 
is often longer than response to classical chemotherapy and even some targeted agents. 
However, response rates in nonselected populations are still low; they are achieved in only 
15–20% of the patients. This fact, together with the high expenses of immunotherapy, leads 
to the necessity of finding reliable predictive biomarkers to identify which patients are most 
likely to benefit from it [16].
5. PD-L1 as a prognostic and predictive biomarker
Programmed cell death protein 1 (PD-1) is a cell surface protein that has two ligands PD-L1 
and PD-L2. PD-1 and PD-L1 negatively regulate immune responses. The PD-1/PD-L1 path-
way mediates one of the mechanisms of cancer “escape” from the immune system. Cancer 
microenvironment induces PD-L1 expression on tumor cells that results in inhibition of the 
immune response, permitting cancer growth, progression, and metastases [5, 18].
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PD-L1 expression has been studied widely in different trials as a prognostic and predictive 
biomarker. Poor responses and high expression of PD-L1 have been found in several cancers 
including melanoma, breast, bladder, ovary, pancreas, kidney, esophagus, and hematologic 
malignancies [1, 18, 19]. Results are not constant; some authors report no correlation or even 
improved survival of patients with tumors highly expressing PD-L1 [18, 20].
Regarding expression of PD-L1 as a prognostic biomarker in lung cancer, several contradictive 
data have been published. Many authors suggest that high expression is connected to better 
prognosis, while others found just the opposite [19]. Cha et al. evaluated the prognostic signifi-
cance of PD-L1 expression in 323 surgically resected lung adenocarcinomas Stages I–III. PD-L1 
expression in tumor cells was positive in 60 of the cases (18.6%). PD-L1 positivity was more 
frequent in male patients (p = 0.001), tumors greater than 3 cm (p = 0.03), higher-stage tumors 
(p < 0.001), solid, predominant tumors (p < 0.001), and EGFR wild-type tumors (p = 0.022). 
Higher expression (over 50%) was more prevalent in former or current smokers compared to 
nonsmokers (p = 0.026) and was associated with more pack-years of smoking (p = 0.016) [19]. 
Survival analysis was performed on 316 patients who underwent complete surgical resection 
(Stages I–IIIA disease). Poor, recurrence-free, and overall survival in patients with high PD-L1 
expression assessed with univariate analysis were reported (both p < 0.001), exact median PFS 
and overall survival (OS) were not reported in numbers (e.g., months). Authors conclude that 
high PD-L1 expression is associated with poor prognosis of patients [19].
Aguiar et al. recently published a meta-analysis aiming to answer the question about PD-L1 as 
a predictive biomarker. The analysis included 13 studies with 1979 patients who were treated 
with checkpoint inhibitors. Five different checkpoint inhibitors were used: nivolumab in six 
trials, atezolizumab in three trials, pembrolizumab in one trial, MEDI4736 in two, and ave-
lumab in one trial. The most frequent histology was nonsquamous NSCLC (67%). Majority of 
the patients were previously treated (84%), male (58%), current or previous smokers (64%), 
and with ECOG performance status 1 (62%). All included trials reported overall response rate 
(ORR). The ORR in 652 PD-L1–positive patients was 29%, and 13% among 915 PD-L1–nega-
tive patients. Difference was statistically significant (relative risk (RR) 2.08, 95% confidence 
interval (CI) 1.49–2.91, p < 0.01). The ORR increased proportionally with increase in PD-L1 
expression, regardless of tumor histology or line of treatment (Pearson’s correlation r = 0.43). 
Regarding PFS, authors evaluated 24 weeks PFS rate. Data were available for 767 patients. In 
PD-L1–positive patients 24 weeks PFS was 35% (358 patients), while in 409 PD-L1–negative 
patients, it was 26% (RR 0.79, 95% CI 0.71–0.89, p < 0.01). One-year overall survival (OS) was 
reported in nine trials with 1396 patients. OS did not differ between the PD-L1–positive and 
PD-L1–negative groups. Among the 617 positive patients the rate was 28%, while among 779 
PD-L1–negative, it was 27% (RR 0, 96, 95% CI 0.87–1.06, p = 0.39). Authors also evaluated the 
response to immune checkpoint inhibitors compared to docetaxel in PD-L1 negative patients 
(PD-L1 expression below 1%). Two Phase III and one Phase II trials compared nivolumab 
or atezolizumab with docetaxel in the second-line setting. Among the 407 PD-L1–negative 
patients, ORR was 12% in both arms (RR 1, 95% CI 0.59–1.7, p = 1). PFS was also similar 
between the two arms (hazard ratio (HR) 0.98, p = 0.93 for PFS). Regarding OS even if not sta-
tistically significant, there was even a trend toward better survival among patients receiving 
checkpoint inhibitors (HR 0.83, p = 0.12). Authors conclude that even if tumor PD-L1 
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 expression is related to improved survival and better outcome of patients with advanced 
NSCLC, PD-L1 currently cannot be considered as a biomarker for selection of patients who 
benefit from immune checkpoint inhibitors treatment since many PD-L1–negative patients 
also benefit from them, and the response is not inferior to the response to chemotherapy [1].
Other authors like Schmidt et al. also evaluated prognostic and predictive values of PD-L1 
expression. Three hundred and twenty-one curatively resected NSCLC patients who had 
available tumor material and clinical data from the Thoracic Departments in Ostrcapepeln, 
Germany, were included. Median age of patients was 66 years and all NSCLC histology 
included, except NSCLC non-other specified. Cut-off for positivity was ≥5% of tumor cells 
PD-L1–positive. Twenty-four percent of cells expressed PD-L1 in NSCLC samples. For the 
whole group, PD-L1 expression was not the prognostic factor for OS (p = 0.256). The better 
survival in the patients with PD-L1–positive tumors compared to patients with no PD-L1 
expression was observed only in some subgroups: squamous histology (HR 0.45, 95% CI 0.25–
0.83, p = 0.005), patients that received adjuvant therapy (HR 0.35, CI 0.14–0.86, p = 0.01), had 
positive lymph nodes reviled by surgery (HR 0.47, CI 0.26–0.85, p = 0.005), and had greater 
tumor size (HR 0.55, CI 0.36–0.84, p = 0.004. According to the authors, these findings suggest 
that PD-L1 expression might be prognostic in these subgroups of patients, but because of the 
small sample size, firm conclusions cannot be done [21].
Cooper retrospectively analyzed 681 Australian patients who underwent surgical resection 
for Stages I–III NSCLC between 1990 and 2008 for PD-L1 expression. Tumors with ≥50% of the 
cells showing positive membrane staining were considered to have high expression of PD-L1. 
Several clinicopathological factors were compared regarding PD-L1 expression. Associations 
were encountered comparing patient’s age, tumor size, and grade. High PD-L1 expression 
was associated with younger patient’s age (p = 0.07). Median age in the “younger” group was 
67 and “older” group 69 years. High PD-L1 expression was statistically significantly higher 
in bigger tumors (median size 45 mm vs. 40 mm, p = 0.02) and tumors with higher histologi-
cal grade (p < 0.01). Even if not statistically significant, squamous and large cell tumors had 
more “high” expression compared with adenocarcinomas (8.1 and 12.5 vs. 5.1% of samples, 
p = 0.13). High PD-L1 expression was not associated with factors such as gender, tumor size, 
stage, nodal involvement, EGFR, k-ras, or ALK mutations. Authors also compared patients’ 
outcome between the two PD-L1 groups. Patients with high expression had longer median 
survival compared to patients with low (113.2 months vs. 85.5 months, p = 0.023). High PD-L1 
as the prognostic factor for better survival was confirmed in Cox model (HR 0.59, 95% CI 
0.4–0.8, p > 0.01). Even if high PD-L1 expression was a prognostic factor in this trial, authors 
conclude that the evidence was still not firm enough to claim its prognostic value, and they 
state that any prognostic significance relates not on single marker of immune signals, but to 
the overall balance of the host-tumor immune response [22].
6. Immune checkpoint inhibitors in lung cancer and PD-L1 as predictive 
biomarker
The aim of cancer immunotherapies is to change the adoptive immune system toward tumor 
rejection. One of the possible approaches is immune checkpoint blockade, which aims to 
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relieve inhibition of immune checkpoints [5, 23]. NSCLC was considered to be an immuno-
therapy nonresponsive tumor type, when the earliest clinical trials with interleukins, vac-
cines, and interferon failed to show clinical benefit. More recently, good treatment responses 
and improved overall survival have been observed with the use of immune checkpoint inhibi-
tors. Patients that respond to these treatments have durable responses that are usually longer 
than responses to chemotherapy or targeted therapies. However, some drawbacks exist in 
nonselected patients’ response and can be seen only in 15–20% of the patients, and the cost of 
these drugs is extremely high [12, 16].
Currently, two checkpoint inhibitors (PD-L1 inhibitors) pembrolizumab and nivolumab are 
being used in everyday clinical practice, but it is supposed that soon others such as atezoli-
zumab, durvalumab, and avalumab will enter into everyday clinical use [24]. Quick develop-
ment of new immunotherapeutic drugs is not followed by proper development in optimal 
biomarkers for patient selection. In clinical trials, anti–PD-1 and anti–PD-L1 antibodies 
produce 20% of response in nonselected population [25]. This can be well seen in the inter-
pretation of clinical trials with nivolumab and pembrolizumab. General conclusions from 
nivolumab trials is that patient selections should not be done on the PD-L1 expression, while 
pembrolizumab trials suggest the opposite [16].
6.1. Nivolumab
CheckMate 017, a Phase III trial, compared treatment with docetaxel in one arm and nivolumab 
in second arm in patients with Stage IIIB or Stage IV squamous NSCLC that progressed on 
the first-line therapy with platinum-containing regimen. From October 2012–December 2013, 
272 eligible patients were included. Patients were randomized to receive either nivolumab at 
dose 3 mg/kg or docetaxel 75 mg/m2 every 3 weeks. The primary endpoint was OS. Median 
age was 63, most were men (76%), had ECOG performance status score 1 (76%), and were 
current or former smokers (92%). The nivolumab group had longer overall survival (9.2 vs. 
6 months, HR 0.59, p < 0.001) and longer progression-free survival (3.5 vs. 2.8 months, 
HR = 0.62, p < 0.001). Response was 20% in nivolumab and 9% in docetaxel arm (p = 0.008). 
PD-L1 expression was assessed retrospectively in 83% (225 of 272) of the patients who under-
went randomization. Patients were categorized as positive if the expression was 1, 5, or 10%. 
No differences in overall survival was found between different expression groups in patients 
that received nivolumab or docetaxel regardless of the percentage (%) of positivity (>1% HR 
0.96, CI 0.45–1.05; >5% HR 0.53, CI 0.3–0.89; >10% HR 0.70, CI 0.47–1.01). Authors concluded 
that the expression of PD-L1 was not a prognostic or a predictive factor for treatment with 
nivolumab [16, 26].
CheckMate 057 was a second Phase III trial comparing nivolumab with docetaxel for patients 
with previously treated nonsquamous NSCLC Stage IIIB or Stage IV that progressed on pre-
vious therapy. From November 2012 to December 2013, 582 patients were randomized to 
receive either 3 mg/kg of nivolumab every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. 
Patients treated with nivolumab had longer overall survival (12.2 vs. 9.4 months, HR 0.73, 
p = 0.002) and a higher response rate (19% vs. 12%, p = 0,02) compared to patients receiv-
ing docetaxel. Differences in PFS were not established (2.3 months for nivolumab vs. 4.2 for 
docetaxel, HR 0.92, CI 0.77–1.11, p = 0.39). PD-L1 expression was evaluated in the same way 
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as in CheckMate 017 with cut-offs at 1, 5, and 10%. PD-L1 testing was performed in 78% (455 
of 582) of the patients. Objective response rate was 9% (CI 5–16) in patients with less than 
1% PD-L1 expression, 36% (CI 26–46) in patients with >5%, and 37 (CI 7–48) in patients with 
more than 10% expression. Similarly, differences were seen in OS, with patients who have 
expression more than 5% (median OS 19.4 months), having longer survival with nivolumab 
treatment compared to patients with expression less than 1% (median OS 10.5 months) 
(p < 0.01). The study showed a predictive association between PD-L1 expression and benefit 
from anti–PD-1 treatment. Although the benefit of nivolumab was observed in the overall 
population, the magnitude of benefit across all the efficacy endpoints appeared to be greater 
among patients whose tumors expressed PD-L1 than among those whose tumors did not 
express PD-L1 [16, 27].
6.2. Pembrolizumab
Keynote 001 was a Phase I trial in which patients received three different schedules of treat-
ment with pembrolizumab (2 mg/kg every 2 weeks, 10 mg/kg every two or every 3 weeks). 
From May 2012 to February 2014, 495 patients with Stage IIIB or Stage IV of NSCLC were 
included. ORR with pembrolizumab treatment was 19.4%, and PFS and OS were 3.7 and 12.5 
months, respectively. PD-L 1 was assessed and cut-off defined at 50% of tumor cells expres-
sion. In defining PD-L1 positivity, authors used received-data-characteristic curves (ROC). 
Prevalence of PD-L1 positivity (>50%) was 23.2, 1–49, 37.6, and 39.2% less than 1%. Among 
patients with the score of at least 50%, the progression-free survival was 6.3 (95% CI 2.9–12.5) 
months, and overall survival was not reached. Progression-free and overall survival were 
shorter among patients with a proportion score of 1–49% or a score of less than 1% than 
among those with a score of at least 50%. Median PFS was 6.1 months (CI 4.2-not reached) 
in positive group and 4 months (CI 2.1–2.4) in <1% group. Median OS was not reached in a 
positive group and 10.4 (CI 5.8-not reached) in <1% group. Authors conclude that a propor-
tion score of at least 50% may represent a new biomarker for the treatment of nonsmall-cell 
lung cancer [16, 25].
Keynote 010 was a Phase II/III trial comparing two schedules of pembrolizumab (2 mg/kg 
every 3 weeks, 10 mg/kg every 3 weeks) with docetaxel 75 mg/m2 for patients with PD-L1 
expression (>1% of tumor cells) that progressed on previous chemotherapy. Between August 
2013 and February 2015, 1034 patients were included. Median overall survival was 10.4 
months with pembrolizumab 2 mg/kg, 12.7 months with pembrolizumab 10 mg/kg, and 8.5 
months with docetaxel. Overall survival was significantly longer for both doses of pembro-
lizumab vs. docetaxel (pembrolizumab 2 mg/kg vs. docetaxel: HR 0.71, 95% CI 0.58–0.88, 
p = 0·0008), and (pembrolizumab 10 mg/kg vs. docetaxel: HR 0.61, 95% CI 0.49–0.75, p < 0·0001). 
Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg, 4.0 months 
with pembrolizumab 10 mg/kg, and 4.0 months with docetaxel, with no significant difference 
for pembrolizumab 2 mg/kg or for pembrolizumab 10 mg/kg. As expected, patients with at 
least 50% of tumor cells expressing PD-L1 had overall survival significantly longer with pem-
brolizumab 2 mg/kg than with docetaxel (median 14.9 months vs. 8.2 months; HR 0·54, 95% CI 
0.38–0.77, p = 0.0002), and with pembrolizumab 10 mg/kg than with docetaxel (17.3 months vs. 
8.2 months; 0.50, 0.36–0.70; p < 0.0001). For this patient population, progression-free survival 
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was also significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5.0 
months vs. 4.1 months, HR 0.59, 95% CI 0.44–0.78, p = 0.0001), and with pembrolizumab 10 mg/kg 
than with docetaxel (5.2 months vs. 4.1 months, 95%, HR 0.59, 95% CI 0.45–0.78, p < 0.0001). 
This trial confirmed the results of Keynote 001 and added additional data to the assumed pre-
dictive value of PD-L1 positivity [16, 28].
6.3. Atezolizumab
PD-L1 expression in trials with atezolizumab is reported somehow differently. First expres-
sion is reported in tumor cells (TC) and immune cells infiltrating tumor (IC) separately. 
Tumors are categorized into four different groups:
• TC3/IC3: at least 10% of cells expressing PD-L1.
• TC2/IC2: at least 5% of cells expressing PD-L1.
• TC1/IC1: at least 1% of cells expressing PD-L1.
• TC0/IC0: less than 1% of cells expressing PD-L1.
The association between the response to atezolizumab and PD-L1 expression was first 
assessed in a Phase I trial of Herbst et al. Two hundred and seventy-seven patients with 
advanced incurable cancer received MPDL-3280A (atezolizumab) intravenously every 3 
weeks. Responses (complete and partial responses) were observed in 32 of 175 (18%) with all 
tumor types including NSCLC, melanoma, renal cell carcinoma, and other tumors (including 
colorectal cancer, gastric cancer, and head and neck squamous cell carcinoma). Authors found 
the association between response and the expression of PD-L1. The association of response 
to atezolizumab treatment and tumor-infiltrating immune cell PD-L1 expression was statisti-
cally significant (p = 0.007), while the association with tumor cell PD-L1 expression was not 
(p = 0.920) [29].
POPLAR was a Phase II trial comparing treatment with atezolizumab with docetaxel in 
patients progressing on previous chemotherapy treatments. One hundred forty-four patients 
between August 2013 and March 2014 randomly received either atezolizumab 1200 mg or 
docetaxel 75 mg/m2 once every 3 weeks. Patients on atezolizumab had longer overall survival 
(12.6 vs. 9.7 months, HR = 0.73, p = 0.04), although no differences in response rate or progres-
sion-free survival were encountered. Higher PD-L1 expression in TC/IC was associated with 
improved overall survival (TC3/IC3 HR 0.49, 95% CI 0.22–1.07, p = 0.068; TC2/3 or IC2/3 HR 
0.54, 95% CI 0.33–0.89. p = 0.014, TC1/2/3 or IC1/2/3 HR 0.59, 95%CI 0.40–0.85, p = 0.005; TC0 
and IC0 HR 1.04. 95% CI 0.62–1.75, p = 0.871). Authors believe PD-L1 expression is predictive 
for atezolizumab’s benefits [16, 30].
BIRCH trial was a Phase II trial in which patients with locally advanced or metastatic 
NSCLC were divided into three cohorts. All the patients received atezolizumab at the dose 
of 1200 mg every 3 weeks. Patients were included if they had TC2–3/IC 2-3 PD-L1 expres-
sion. One hundred thirty-nine patients in Cohort I received atezolizumab as first-line treat-
ment, 267 patients in Cohort II as second, and 253 in Cohort III as third or more line of 
treatment. Higher PD-L1 expression was associated with higher response rate in all cohorts. 
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Name of the 
trial (phase) Compound
PD-L1 expression and OS 
(HR compared to control 
arm or months)
PD-L1 expression and 
PFS (HR compared to 
control arm or months)
PD-L1 expression 
and RR (%)
Checkmate 017 
(Phase 3)
Nivolumab versus 
docetaxel
<1% (0.58)
≥1% (0.69)
<5% (0.70)
≥5% (0.53)
<10% (0.70)
≥10% (0.50)
<1% (0.66)
≥1% (0.67)
<5% (0.75)
≥5% (0.54)
<10% (0.70)
≥10% (0.58)
<1% (17)
≥1% (17)
<5% (15)
≥5% (21)
<10% (16)
≥10% (19)
Checkmate 057 
(Phase III)
Nivolumab versus 
docetaxel
<1% (0.90)
≥1% (0.59)
<5% (1.01)
≥5% (0.43)
<10% (1.00)
≥10% (0.40)
<1% (1.19)
≥1% (0.70)
<5% (1.31)
≥5% (0.54)
<10% (1.24)
≥10% (0.52)
<1% (9)
≥1% (31)
<5% (10)
≥5% (36)
<10% (11)
≥10% (37)
Keynote 001 
(Phase I)
Pembrolizumab <1% 10.4 months
1–49% 10.6 months
≥50% not repoted
<1% 4.0 months
1–49% 4.1 months
≥50% 6.4 months
<1% (10.7)
1–49% (16.5)
≥50% (45.2)
Keynote 010 
(Phase III)
Pembrolizumab 2 mg/kg 
versus docetaxel
>1% (0.71)
≥50% (0.54)
>1% (0.88)
≥50% (0.59)
>1% (18)
≥50% (30)
Keynote 010 
(Phase III)
Pembrolizumab 10 mg/kg 
versus docetaxel
>1% (0.61)
≥50% (0.50)
>1% (0.79)
≥50% (0.59)
>1% (18)
≥50% (29)
Atezolizumab 
(Phase I)
Atezolizumab TC0–2/IC0–2 16 months
TC3/IC3
18 months
TC0–2/IC0–2
4 months
TC3/IC3
4 months
TC0–2/IC0–2 (16)
TC3/IC3
(48)
POPLAR  
(Phase 2)
Atezolizumab versus 
docetaxel
TC0/IC (1.04)
TC0–2/IC 0–2 (0.59)
TC2–3/IC 2–3 (0.54)
TC3/IC3 (0.49)
TC0/IC (1.12)
TC0–2/IC 0–2 (0.85)
TC2–3/IC 2–3 (0.72)
TC3/IC3 (0.60)
TC0/IC (8)
TC0–2/IC 0–2 (18)
TC2–3/IC 2–3 (22)
TC3/IC3 (38)
BIRCH (Phase 
II, Cohort I)
Atezolizumab TC2–3/IC2–3 (82%)*
TC3/IC3 (79%)*
TC2–3/IC2–3
5.5 months
TC3/IC3
5.5 months
TC2–3/IC2–3 (19)
TC3/IC3 (26)
BIRCH (Phase 
II, Cohort II)
Atezolizumab TC2–3/IC2–3 (76%)*
TC3/IC3 (80%)*
TC2–3/IC2–3
2.8 months
TC3/IC3
4.1 months
TC2–3/IC2–3 (17)
TC3/IC3 (24)
BIRCH (Phase 
II, Cohort III)
Atezolizumab TC2–3/IC2–3 (71%)*
TC3/IC3 (75%)*
TC2–3/IC2–3
2.8 months
TC3/IC3
4.2 months
TC2–3/IC2–3 (17)
TC3/IC3 (27)
Avelumab 
(Phase Ib)
Avelumab >1% (4.6 months)
≤1% (8.9 months)
>1% (5.9 weeks)
≤1% (12.0 weeks)
>1% (10)
≤1% (15)
Durvalumab 
(Phase I/II)
Durvalumab <25% not reported
≥25% not reported
<25% not reported
≥25% not reported
<25% (5)
≥25% (27)
*Six-month overall survival.
Table 1. Response to checkpoint inhibitors according to PD-L1 expression.
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In Cohort I, ORR was 26% (95% CI 16–39) in patients with TC3/IC2 vs. 19% (95% CI 13–27) 
in patients with TC2–3/IC 2–3. In Cohort II, ORR was 24% (95% CI 17–32) in patients with 
TC3/IC2 vs. 17% (95% CI 13–22) in patients with TC2–3/IC 2–3. In Cohort III ORR was 27% 
(95% CI 19–36) in patients with TC3/IC2 vs. 17% (95% CI 13–23) in patients with TC2–3/
IC 2–3. These results also suggest that PD-L1 is a possible biomarker for treatment with 
atezolizumab [31].
6.4. Avelumab and durvalumab
Patients received avelumab in a Phase Ib trial. The response rate, median progression-free 
survival, and median overall survival were 13.6%, 11.6 weeks and 8.4 months. PD-L1 cut-off 
for positivity was 1% of the expression and was associated with higher response rate, longer 
progression-free, and overall survival [16]. Response rate of 16% was achieved in Phase I/II 
trial of durvalumab treatment. PD-L1 positivity was defined as an expression of more than 
25% of cells and was correlated with higher response rate [16].
Trials with checkpoint inhibitors are summarized in Table 1.
7. The problems of PD-L1 as a biomarker
The assessment of PD-L1 tumor expression is currently a controversial issue with more open 
questions than known facts. PD-L1 expression is a dynamic rather than static process that var-
ies according to different tumor and host factors (15–30). Several data show that anti–PD-L1 
drugs are more effective in patients whose tumors express PD-L1, but responses in the popu-
lation of patients without the expression lead to the conclusion that these patients also benefit 
from this treatment. How to select right patients for anti–PD-L1 treatment remains an open 
question in these circumstances [5].
7.1. Tests
Currently, several different monoclonal antibodies for testing PD-L1 positivity exist. In 
a meta-analysis of Aguiar et al. among 13 included trials, 5 different antibodies were used 
(DAKO 28-8, DAKO 22C3, VENTANA SP 142, and two nonspecified), and 3 different thresh-
old values for immunohistochemical positivity selected (1, 5, and 50%). Authors conclude that 
standardized approach to PD-L1 status assessment is lacking [1]. For the details of Aguiar’s 
meta-analysis, please see the Section 5 of this chapter.
Today several differences exist between tests:
1. Every test uses it own antibody.
2. Some tests evaluate the percentage of tumor cells stained, while others evaluate not only 
tumor cells but also tumor infiltrating immune cells.
3. Cut-off points and scoring systems differ between tests.
4. Different staining techniques (manual vs. automated).
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All these differences make the comparison between results of different tests difficult if not 
impossible [16, 23].
7.2. Positivity and response to treatment
The threshold of immunohistochemical PD-L1 expression positivity is not well established 
today. Thresholds of 1, 5, or 50% of positive cells are being used in different trials. It is esti-
mated that any expression of PD-L1 can be found in 45–50% of NSCLC biopsies [18]. In a 
trial of Cha et al., the threshold of 5% showed the most significant p value regarding overall 
survival predictions [19]. For details of Cha et al. trial, please see the Section 5 of this chapter. 
Even if considered positive (regardless of the positivity cut-off), not all patients respond to the 
treatment with immunotherapy. Response is seen only in 15–45% of “positive” patients and 
on the other end, many “negative” patients also respond [16].
7.3. Concordance
Checkpoint inhibitors recently demonstrated efficacy in the treatments of metastatic NSCLC 
that are being used more and more in clinical trials and everyday clinical practice. Despite 
their benefits, the association of responses with a predictive biomarker PD-L1 remains uncer-
tain. Today, several PD-L1 IHC tests exist, and concordance between them is not very clear. 
Sheffield et al. compared multiple methods of testing. Tissue microarrays of matched primary 
and metastatic NSCLCs were used to compare four different PD-L1 IHC techniques. Tissues 
from 80 patients were included. Multiple IHC methodologies showed a high rate of agreement 
(Kappa = 0.67). Concordance between PD-L1 positivity among different tests (antibodies) 
was from 73.4 to 76%. Determination of which test is the best one is challenging due to the lack 
of a reference standard [32].
Significant discordance between the PD-L1 status of primary tumors and metastases was 
observed. PD-L1 status of primary and metastatic tumors was discordant in 17 (22%) cases. 
Because of the variability of the biomarker, also changes in positivity during immunotherapy 
treatment have been studied. Discordance between primary tumor and metastatic sites is sup-
posed to be because of the intratumoral heterogeneity and sampling bias [32]. Variability 
seems to be even more substantial, since immunohistochemical status changes during treat-
ment in 12–35% of the patients [16].
7.4. Tissue
Keynote 001 trial revealed another unanswered issue in the PD-L1 expression testing. 
Deterioration in the PD-L1 expression in archival tissue samples that had been sectioned 6 
months or more before testing was encountered. Researches decided to evaluate only the 
samples taken in the 6-months period before testing. Of the 1143 screened patients, only 824 
had eligible tumor samples. Why this deterioration in expression occurs, and how to treat 
patients with pembrolizumab that do not have tissue available for testing are another of the 
two questions to be solved [25].
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7.5. Open questions
To be able to continue the story of the PD-L1 as a predictive biomarker, these open questions 
will have to be answered [33]:
1. Is a predictive biomarker in immunotherapy necessary?
2. Is localization of the biomarker important (expression of PD-L1 in tumor and/or tumor-
infiltrating lymphocytes)?
3. What is/are the optimal detection test/tests?
4. Does PD-L1 expression change over time (after different treatments such as chemotherapy 
and irradiation) and space (primary tumor vs. metastases)?
8. Conclusion
Immune checkpoint inhibitors are new and very promising treatment options in patients with 
several solid malignancies including lung cancer. For an optimal selection of patients who bene-
fit most, predictive biomarkers are needed. PD-L1 has been suggested as a potential biomarker, 
but due to many open questions, today, it is not considered the only reliable immunotherapy 
biomarker since responses can be encountered even in patients considered PD-L1 negative. A 
possible solution to this issue is finding new and maybe more reliable predictive biomarkers 
that will for sure evolve in the next years of immunotherapy treatment development.
Author details
Mirjana Rajer
Address all correspondence to: mrajer@onko-i.si
Institute of Oncology Ljubljana, Ljubljana, Slovenia
References
[1] Aguiar, P.N., Jr., et al., The role of PD-L1 expression as a predictive biomarker in 
advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy, 2016. 
8(4): pp. 479–488.
[2] Homet Moreno, B. and Ribas, A., Anti-programmed cell death protein-1/ligand-1 ther-
apy in different cancers. Br J Cancer, 2015. 112(9): pp. 1421–1427.
[3] McDermott, D.F. and Atkins, M.B., PD-1 as a potential target in cancer therapy. Cancer 
Med, 2013. 2(5): pp. 662–673.
Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer
http://dx.doi.org/10.5772/66757
125
[4] Domagala-Kulawik, J., The role of the immune system in non-small cell lung carci-
noma and potential for therapeutic intervention. Transl Lung Cancer Res, 2015. 4(2): pp. 
177–190.
[5] Aguiar, P.N., Jr., et al., A pooled analysis of nivolumab for the treatment of advanced non-
small-cell lung cancer and the role of PD-L1 as a predictive biomarker. Immunotherapy, 
2016. 8(9): pp. 1011–1019.
[6] Janssen-Heijnen, M.L. and Coebergh, J.W., Trends in incidence and prognosis of the 
histological subtypes of lung cancer in North America, Australia, New Zealand and 
Europe. Lung Cancer, 2001. 31(2–3): pp. 123–137.
[7] Janssen-Heijnen, M.L. and Coebergh, J.W., The changing epidemiology of lung cancer in 
Europe. Lung Cancer, 2003. 41(3): pp. 245–258.
[8] Charloux, A., et al., The increasing incidence of lung adenocarcinoma: reality or artefact? 
A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol, 1997. 26(1): pp. 
14–23.
[9] Burns, D.M., Changing rates of adenocarcinoma of the lung. Chem Res Toxicol, 2014. 
27(8): pp. 1330–1335.
[10] Santarpia, M., et al., Programmed cell death protein-1/programmed cell death ligand-1 
pathway inhibition and predictive biomarkers: understanding transforming growth 
factor-beta role. Transl Lung Cancer Res, 2015. 4(6): pp. 728–742.
[11] Zamarin, D. and Postow, M.A., Immune checkpoint modulation: rational design of com-
bination strategies. Pharmacol Ther, 2015. 150: pp. 23–32.
[12] Chakravarti, N. and Prieto, V.G., Predictive factors of activity of anti-programmed 
death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl 
Lung Cancer Res, 2015. 4(6): pp. 743–751.
[13] Ballman, K.V., Biomarker: predictive or prognostic?. J Clin Oncol, 2015. 33(33): pp. 
3968–3971.
[14] Chan, J.Y., Choudhury, Y., and Tan, M.H., Predictive molecular biomarkers to guide 
clinical decision making in kidney cancer: current progress and future challenges. 
Expert Rev Mol Diagn, 2015. 15(5): pp. 631–646.
[15] Burotto, M., et al., Biomarkers in early-stage non-small-cell lung cancer: current concepts 
and future directions. J Thorac Oncol, 2014. 9(11): pp. 1609–1617.
[16] Shukuya, T. and Carbone, D.P., Predictive markers for the efficacy of Anti-PD-1/PD-L1 
antibodies in lung cancer. J Thorac Oncol, 2016. 11(7): pp. 976–988.
[17] Falconi, A., Lopes, G., and Parker, J.L., Biomarkers and receptor targeted therapies 
reduce clinical trial risk in non-small-cell lung cancer. J Thorac Oncol, 2014. 9(2): pp. 
163–169.
[18] D’Incecco, A., et al., PD-1 and PD-L1 expression in molecularly selected non-small-cell 
lung cancer patients. Br J Cancer, 2015. 112(1): pp. 95–102.
A Global Scientific Vision - Prevention, Diagnosis, and Treatment of Lung Cancer126
[19] Cha, Y.J., et al., Clinicopathological and prognostic significance of programmed cell 
death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. 
Lung Cancer, 2016. 97: pp. 73–80.
[20] Baxevanis, C.N., et al., Immune biomarkers: how well do they serve prognosis in human 
cancers?. Expert Rev Mol Diagn, 2015. 15(1): pp. 49–59.
[21] Schmidt, L.H., et al., PD-1 and PD-L1 expression in NSCLC indicate a favorable progno-
sis in defined subgroups. PLoS One, 2015. 10(8): p. e0136023.
[22] Cooper, W.A., et al., PD-L1 expression is a favorable prognostic factor in early stage non-
small cell carcinoma. Lung Cancer, 2015. 89(2): pp. 181–188.
[23] Chae, Y.K., et al., Biomarkers for PD-1/PD-L1 blockade therapy in non-small-cell lung 
cancer: is PD-L1 expression a good marker for patient selection?. Clin Lung Cancer, 
2016. 17(5): pp. 350–361.
[24] Grigg, C. and Rizvi, N.A., PD-L1 biomarker testing for non-small cell lung cancer: truth 
or fiction?. J Immunother Cancer, 2016. 4: p. 48.
[25] Garon, E.B., et al., Pembrolizumab for the treatment of non-small-cell lung cancer. N 
Engl J Med, 2015. 372(21): pp. 2018–2028.
[26] Brahmer, J., et al., Nivolumab versus docetaxel in advanced squamous-cell non-small-
cell lung cancer. N Engl J Med, 2015. 373(2): pp. 123–135.
[27] Borghaei, H., et al., Nivolumab versus docetaxel in advanced nonsquamous non-small-
cell lung cancer. N Engl J Med, 2015. 373(17): pp. 1627–1639.
[28] Herbst, R.S., et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-
positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised con-
trolled trial. Lancet, 2016. 387(10027): pp. 1540–1550.
[29] Herbst, R.S., et al., Predictive correlates of response to the anti-PD-L1 antibody 
MPDL3280A in cancer patients. Nature, 2014. 515(7528): pp. 563–567.
[30] Fehrenbacher, L., et al., Atezolizumab versus docetaxel for patients with previously 
treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 ran-
domised controlled trial. Lancet, 2016. 387(10030): pp. 1837–1846.
[31] Besse, B., et al., 16LBA phase II, single-arm trial (BIRCH) of atezolizumab as first-line 
or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell 
lung cancer (NSCLC). Eur J Cancer, 2015. 51: pp. S717–S718.
[32] Sheffield, B.S., et al., Investigation of PD-L1 biomarker testing methods for PD-1 axis 
inhibition in non-squamous non-small cell lung cancer. J Histochem Cytochem, 2016. 
64(10): 587–600.
[33] Sundar, R., et al., Immunotherapy in the treatment of non-small cell lung cancer. Lung 
Cancer, 2014. 85(2): pp. 101–109.
Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer
http://dx.doi.org/10.5772/66757
127

